Axovant Sciences Ltd. (NYSE:AXON)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Robert W. Baird in a research note issued on Friday. They presently have a $29.00 target price on the stock. Robert W. Baird’s target price suggests a potential upside of 104.37% from the company’s current price.
AXON has been the subject of several other reports. Piper Jaffray Cos. set a $32.00 price objective on shares of Axovant Sciences and gave the stock a “buy” rating in a research note on Friday, September 23rd. Zacks Investment Research upgraded shares of Axovant Sciences from a “hold” rating to a “strong-buy” rating and set a $15.00 price objective for the company in a research note on Tuesday, October 18th. Jefferies Group reiterated a “buy” rating and set a $31.00 price objective on shares of Axovant Sciences in a research note on Thursday, November 17th. JMP Securities reiterated an “outperform” rating and set a $36.00 price objective on shares of Axovant Sciences in a research note on Tuesday, August 16th. Finally, HC Wainwright reiterated a “buy” rating on shares of Axovant Sciences in a research note on Tuesday, November 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $26.33.
Axovant Sciences (NYSE:AXON) traded up 0.50% on Friday, hitting $14.19. The company’s stock had a trading volume of 92,892 shares. The firm has a 50 day moving average of $13.09 and a 200 day moving average of $13.79. Axovant Sciences has a 12 month low of $8.86 and a 12 month high of $21.30. The firm’s market cap is $1.41 billion.
Hedge funds and other institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN boosted its stake in Axovant Sciences by 1.5% in the third quarter. Wells Fargo & Company MN now owns 8,130 shares of the company’s stock worth $113,000 after buying an additional 117 shares in the last quarter. SG Americas Securities LLC bought a new stake in Axovant Sciences during the third quarter worth approximately $124,000. GSA Capital Partners LLP bought a new stake in Axovant Sciences during the second quarter worth approximately $128,000. Princeton Capital Management Inc. bought a new stake in Axovant Sciences during the third quarter worth approximately $145,000. Finally, Royal Bank of Canada boosted its stake in Axovant Sciences by 467.6% in the second quarter. Royal Bank of Canada now owns 10,500 shares of the company’s stock worth $135,000 after buying an additional 8,650 shares in the last quarter. Institutional investors and hedge funds own 28.46% of the company’s stock.
About Axovant Sciences